Geoffrey Barnes, MD, MSc
Vascular Cardiologist at Univ of Michigan Frankel Cardiovascular Center
#thrombosis, #CVcoag, #ImpSci
Co-director of MAQI2 and MPrOVE
Board of Directors and President-elect of the Anticoagulation Forum
🏳️🌈
- Dr Pam Morris reminds the @medscape.com #HeartofCardio attendees that bempedoic acid is a pro-drug that is only activated in the liver. So there is no active drug in muscle - that’s why it should not lead to any myalgia!
- Check out this great CME season focused on Factor XI inhibitors. Lots of great science coming out over the next 3 months that every cardiovascular specialist will want to know!
- 1/21 In this #CME, Geoff Barnes, MD provides the latest information on investigational factor XI/XIa (FXI/XIa) inhibitors and their potential role in managing stroke risk in patients with AF. Get credit: link.med-iq.com/PBVC33
- Last month, I was honored to visit several hospitals across China to share cardiovascular knowledge with their physicians and trainees. I was humbled by their incredible research work and the immense clinical knowledge they shared with me. Looking forward to future visits! @accintouch.bsky.social
- Reposted by Geoffrey Barnes, MD, MSc⏰ Have you listened to our latest ISTH Pulse podcast episode? If PE care is part of your clinical practice, this episode is must-listen. 🎧 Catch up on the episode and hear what these findings could mean for PE management moving forward: bit.ly/3YCUUgJ. This episode is supported by Penumbra.
- Reposted by Geoffrey Barnes, MD, MScSo proud of our board members and AC Forum experts for their new article in JTH “Anticoagulation Stewardship from Menstruation to Menopause: A Toolkit for Clinical Management.” 👏 Read the article today: www.jthjournal.org/article/S153...
- Reposted by Geoffrey Barnes, MD, MScBalancing thrombosis and bleeding risk isn't simple. Get closer to the conversations that matter with our NEW expert roundtable, chaired by @gbarnesmd.bsky.social. Watch now for practical takeaways on the latest trial data in #thrombosis care #MedSky #CardioSky #HaemSky ow.ly/r2rk50XGYub
- Reposted by Geoffrey Barnes, MD, MScWhat awaits you at the #ISTH2026 Congress & why should you submit abstracts & participate? In the latest @ISTH.org Pulse podcast W. Ageno 🇮🇹 @cihanaymd.bsky.social 🇦🇹 & host @gbarnesmd.bsky.social 🇺🇸 go behind the scenes of the congress preps. 🎧Listen & join the journey to Paris 🇫🇷: bit.ly/48PRg9a
- Reposted by Geoffrey Barnes, MD, MScTune in to hear @gbarnesmd.bsky.social and @bbikdeli.bsky.social present their round-up of this year's major advances in VTE and AF management. Stay ahead in thrombosis care with insights on recent trial data and the shift towards treatment personalization #MedSky #CardioSky ow.ly/Lnm450XBnMr
- Reposted by Geoffrey Barnes, MD, MScAccompanying this research is an 🔥 editorial by Drs. Thomas Cascino & @gbarnesmd.bsky.social that analyzes the article & advocates for a systematic evaluation of disparities to enhance care in HF. 🔗 bit.ly/3JvsFgi
- There was so much to cover in 2025... we only were able to discuss the "tip of the iceberg." Still - so much great science that we explored togehter. Thanks @bbikdeli.bsky.social for joining me on the podcast!
- Tune in to hear @gbarnesmd.bsky.social and @bbikdeli.bsky.social present their round-up of this year's major advances in VTE and AF management. Stay ahead in thrombosis care with insights on recent trial data and the shift towards treatment personalization #MedSky #CardioSky ow.ly/Lnm450XBnMr
- I had the most wonderful conversation with @lesllake.bsky.social for the Think Thrombosis podcast from @medthority.bsky.social . Be sure to check it out! www.medthority.com/medical-educ...
- Reposted by Geoffrey Barnes, MD, MScCan #AI keep up with #thrombosis specialists🤔? In the latest @ISTH.org Pulse Podcast episode guest @nikola-vladic.bsky.social & host @gbarnesmd.bsky.social dive into the data, incl. how AI stacked up against experts in patient education & clinical decision-making 🎧http://bit.ly/3X9FMH4
- I enjoyed talking all things anticoagulation and thrombosis with Dr Bikdeli for the @medthority.bsky.social Think Thrombosis podcast! www.medthority.com/medical-educ...
- Reposted by Geoffrey Barnes, MD, MSc💡 How do you bring AC Forum tools to life in your own clinic? Join us on Thursday, November 13 at 12:00 pm ET for a new webinar, walking you through practical examples of how clinicians use AC Forum’s stewardship tools, patient cases, and training resources. Register today: bit.ly/46SFcSA
- Reposted by Geoffrey Barnes, MD, MSc[Not loaded yet]
- Connie Hess reminds #AHA25 attendees that patients with PAD are at risk for both MACE and MALE. But the specific risk factors and risk spectrum differ for those two adverse outcomes.
- Why do clinicians “underdose” DOAC therapy? Sara Vasquez teaches us that there are 3 main drivers! How to address these? #AntithromboticStewardship
- Here are a few examples of #AntithromboticStewardship interventions. #AHA25
- Akhi Sista nicely compares and contrasts the purpose of the 4 ongoing RCTs in acute PE interventions. #TheVEINS25
- According to Aditya Sharma, Virchow’a Triad is “out” and the Quartet of Thrombosis is “in”! Now we need to figure out how to target the underlying inflammation that contributes to VTE risk and recurrence risk. #TheVEINS25
- Reposted by Geoffrey Barnes, MD, MSc
- Reposted by Geoffrey Barnes, MD, MSc[Not loaded yet]
- Reposted by Geoffrey Barnes, MD, MScThis #WorldStrokeDay, get the updates you need to know with our expert podcast series, Thrombosis in Conversation, hosted by @gbarnesmd.bsky.social. Stay ahead with highlights from #ESC2025, plus insights from Deborah Siegal on optimizing treatment duration #MedSky #CardioSky ow.ly/hh0S50XjNC4
- Reposted by Geoffrey Barnes, MD, MScFactor XI levels and left atrial appendage thrombosis ⬇️ 📌 Elevated Factor XI levels were linked to left atrial appendage thrombi of unknown origin, their recurrence, and higher risk of cerebrovascular events 🧠 Read 👉 www.thieme-connect.de/products/ejo...
- A beautiful fall morning!
- Reposted by Geoffrey Barnes, MD, MScMissed the 2025 Virtual Boot Camp? There’s still time to catch every session, insight, and CE credit opportunity — all on your own time! Don't wait, the registration is only available through November 7, and full access until November 18 🔗 Register here or share it with a colleague: bit.ly/41eozi4
- Reposted by Geoffrey Barnes, MD, MScTune into the latest episode of the @ISTH.org Pulse Podcast! Moderator @gbarnesmd.bsky.social & speakers Victor Tapson & Andrew Niekamp explore how mechanical thrombectomy is transforming the treatment landscape for #VTE. 📺 bit.ly/4qjLBze 🎧 bit.ly/4qcJJYH #WTDay25
- Reposted by Geoffrey Barnes, MD, MSc🩸 World Thrombosis Day is here! Want to understand thrombosis better and hear powerful insights? 🎧 Tune in to our episodes now - sites.libsyn.com/564815 ! Let’s raise awareness, spark conversations, and make a difference. 💬 Listen, learn, and share. #WorldThrombosisDay #ThrombosisAwareness
- Reposted by Geoffrey Barnes, MD, MSc🩸 World Thrombosis Day is here! Let’s raise awareness and share new insights in thrombosis and hemostasis. Have research to share? We want to see it! ➡️ Submit your work to TH OPEN, the open-access companion journal of TH. 🔗 Submit here lp.thieme.de/journals/th-... ✨ Impact Factor 2024: 1.8
- Reposted by Geoffrey Barnes, MD, MScDid you know blood clots are often preventable? Top risk factors: - Immobility - Surgery, major injury - Cancer, certain treatments - Family or personal history - Hormones, pregnancy or postpartum From head to toe, take control. 💙 #BloodClotAwareness #WorldThrombosisDay #WTDay25
- Reposted by Geoffrey Barnes, MD, MScToday my @nytimes.com colleagues and I are launching a new series called Lost Science. We interview US scientists who can no longer discover something new about our world, thanks to this year‘s cuts. Here is my first interview with a scientist who studied bees and fires. Gift link: nyti.ms/3IWXbiE
- Reposted by Geoffrey Barnes, MD, MScNEW episode: Which studies presented at #ESCCongress showed practice-changing results in thrombosis management? Listen to @gbarnesmd.bsky.social and @mproiettimd.bsky.social discuss the updates you need to know on venous thromboembolism and atrial fibrillation #MedSky #ESC2025 ow.ly/VPOt50X0iuz
- Reposted by Geoffrey Barnes, MD, MSc🎧 to the new episode of the @isth.org Pulse Podcast feat. @worldthrombosisday.bsky.social Patient Ambassador Carol West who highlights the vital role patients play in raising #awareness, driving #research & inspiring #change In her interview w/host @gbarnesmd.bsky.social #WTDay25 bit.ly/4nJ6Kkv
- Reposted by Geoffrey Barnes, MD, MSc[Not loaded yet]
- Reposted by Geoffrey Barnes, MD, MScThe ISTH is seeking applications for the 2028 ACPC Chair. You’ll play a pivotal role in shaping the scientific program of ISTH 2028 in Europe 🌍 ✅Open to active ISTH members in good standing ✅Preference for candidates from Europe ✅Must bring strong leadership 👉 Learn more: bit.ly/4gRaXQr
- Reposted by Geoffrey Barnes, MD, MScHappy World Pharmacists Day! 💊 We celebrate the pharmacists who play a vital role in advancing safe, effective, and evidence-based anticoagulation care. From stewardship to education, research, & direct patient care, pharmacists are essential partners in improving outcomes for patients worldwide.
- There are so many unanswered questions in acute PE management. Thankfully, we’re finally getting some RCTs to help answer them! #PERT2025
- Reposted by Geoffrey Barnes, MD, MScMy patient recently lost his Medicaid insurance and couldn’t afford his meds. Just calculated the cost of his 13 💊 which would be $2300/month. That’s around $27,500/year. The FPL for a family of 4 is ~$32,000. This is not sustainable for the health and lives of our patients! #Pharmacoequity
- I'm honored to work with such a talented, diverse, and dedicated group of scientists and clinicians to plan the upcoming #ISTH2026 meeting - lots of great science with innovative and engaging education formats being planned!!
- Our Annual Congress Planning Committee (ACPC) is hard at work in Paris this week, laying the groundwork for an unforgettable #ISTH2026! The best is yet to come! Learn more here: www.isthcongress.org
- I was thrilled to be joined by Prof Marco Proietti to discuss important #VTE and #AFib trials presented at the ESC meeting. Lots of great science that impacts how we care for patients with #cvCoag meds. www.medthority.com/medical-educ... @medthority.bsky.social
- Reposted by Geoffrey Barnes, MD, MScGreat news. Let's do this everywhere. www.krqe.com/news/politic...
- Reposted by Geoffrey Barnes, MD, MSc🎙️ New ISTH Pulse Podcast episode! APS is one of the most complex conditions in thrombosis & anticoagulation strategies vary. Join host Dr. Barnes and APS expert Dr. Arachchillage as they discuss evolving guidance, the role of DOACs & how clinicians can support patient care. 👉 bit.ly/48ablao
- Reposted by Geoffrey Barnes, MD, MSc🎙️New ISTH Pulse Podcast episode! Nearly 40 years ago, Dr. Israels & Dr. Rand met at an ISTH Congress. Today, the two colleagues & friends sit down to discuss their research, careers & how the ISTH helped them cultivate a lifelong friendship 👉bit.ly/41pyVvK
- Reposted by Geoffrey Barnes, MD, MSc💡Listen to the latest ISTH Pulse Podcast & learn how the @ISTH.org Guidelines & Guidance Comm. (G&G) advances clin. practice worldwide! Host @gbarnesmd.bsky.social speaks w/ @fniainle.bsky.social , G&G Committee Chair about the process behind developing GLs & next projects. 🎧https://bit.ly/45kh6Rf
- Reposted by Geoffrey Barnes, MD, MScBreaking: The AAP has released its own evidence-based vaccine schedule, after recent federal changes prioritized politics over evidence. Americans have long trusted their pediatricians. We ask for your trust again on this. Science first. Kids first. downloads.aap.org/AAP/PDF/AAP-...
- Reposted by Geoffrey Barnes, MD, MScI talked with a doctor in rural Wisconsin about what she wished elected officials in Washington understood about the health care system. Her answer is important for every American to hear:
- Reposted by Geoffrey Barnes, MD, MScA new @thrombosiscan.bsky.social survey found that >50% of Canadian cancer patients have little or no awareness of cancer-associated thrombosis (CAT) — a major cause of death in cancer. 📊 Only 27% recalled being educated on CAT risks, yet most want more info! doi.org/10.1055/a-26...
- Reposted by Geoffrey Barnes, MD, MSc2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Medical Weight Management for Optimization of Cardiovascular Health by Drs. Gilbert, @drmarthagulati.bsky.social, Gluckman, @mkittlesonmd.bsky.social, Rikhi, Saseen, Tchang
- Reposted by Geoffrey Barnes, MD, MSc[Not loaded yet]
- Reposted by Geoffrey Barnes, MD, MScFor some weekend listening, tune into this new and interesting @ISTH.org Pulse Podcast episode. 🎧Listen as host @gbarnesmd.bsky.social and guest Mark Thomas discuss 💡"Using Artificial Intelligence to Treat Thrombotic Conditions" ⬇️ bit.ly/3HptMwX
- Reposted by Geoffrey Barnes, MD, MScOur Anticoagulation Literature Library was just updated with 52 new publications - curated to keep you sharp, informed, & confident in your clinical decision-making. Whether you are navigating complex cases or staying on top of evolving evidence, this free resource is built for you: bit.ly/48YC2NC
- Reposted by Geoffrey Barnes, MD, MSc[Not loaded yet]
- Reposted by Geoffrey Barnes, MD, MSc💡Plan to attend the next @ISTH.org webinar on "Global Perspectives of Anticoagulation Stewardship" 🗓️July 30 at 21:30 UTC Speakers Hadley Bortz 🇦🇺 & @jorimay.bsky.social 🇺🇸 will share their regional perspectives & expertise, followed by a live Q&A session. bit.ly/4kBC3M6
- 🚀 Thrilled to announce I’ll be speaking at the 6th Annual Going Back to the Heart of Cardiology in Miami Beach January 30-February 1, 2026! Get ready for the latest breakthroughs in Cardiology and more. Excited to meet everyone! Register here: www.heartofcardio.com #HeartofCardio ❤️
- Reposted by Geoffrey Barnes, MD, MScHere's a great example of our members using data from our National Poll on Healthy Aging in a journal article on preventive aspirin use by older adults: Summary: ihpi.umich.edu/news-events/... Paper in @jaccjournals.bsky.social : www.sciencedirect.com/science/arti... @gbarnesmd.bsky.social #medsky
- Reposted by Geoffrey Barnes, MD, MSc💡Don't miss the latest in the world of #thrombosis & #hemostasis w/the @ISTH.org Pulse Podcast. 🎙️Hosts @gbarnesmd.bsky.social & @btsamuelsonmd.bsky.social bring you insightful interviews and stories with guest from around the T+H world. 🎧Subscribe & listen: pod.link/1555328920
- Reposted by Geoffrey Barnes, MD, MScWe met some fantastic people at #ISTH2025 dedicated to improving thrombosis and anticoagulation care! But don't let the learning stop! The AC Forum provides the resources and connections you need to stay at the forefront of anticoagulation care. 👉 Join the AC Forum for FREE: bit.ly/3YX2aFw
- Reposted by Geoffrey Barnes, MD, MSc🐝 Heard the buzz about the ISTH Pulse Podcast at #ISTH2025? 🎧Our hosts @gbarnesmd.bsky.social and @btsamuelsonmd.bsky.social are here to share why this podcast is making waves in the thrombosis and hemostasis world. Watch the video now: www.isthcongressdaily.org/articles/Art...
- Many people wonder if the severity of an acute PE influences VTE recurrence risk and therefore should impact DOAC dose selection? A post-hoc analysis of RENOVE study shows similar rates or recurrent VTE based on PE severity. #ISTH2025
- Factor XI inhibition is a promising target for preventing thrombosis with a low rate of bleeding. Currently phase 3 trials use small molecule inhibitors or monoclonal antibodies. SRSD107 is an siRNA agent that prevents FXI production. Is 2x-yearly treatment for thrombosis on the horizon? #ISTH2025
- If you want to learn more about Factor XI inhibitors, check out this recent review article in @jthjournal.bsky.social pubmed.ncbi.nlm.nih.gov/39675564/
- I often get asked if DOAC therapy is safe for patients with thrombophilia. We know that standard dose DOAC works well. But what about reduced DOAC dose after the initial 3-6 months of VTE treatment? #ISTH2025
- This prospective study explored the important question of DOAC dose in 200 consecutive patients with thrombophilia and VTE. A little over 2 years of follow up! #ISTH2025
- Of the patients who received reduce-dose DOAC, rate of recurrent VTE was reassuringly low! #ISTH2025
- The cumulative incidence curve for VTE recurrence and bleeding was similar for full dose and reduce dose DOAC in thrombophilia-VTE. #ISTH2025
- Reposted by Geoffrey Barnes, MD, MScImplementation matters! A guideline-driven VTE prevention program (Vermont Model) led to ~60% of high-risk cancer patients receiving prophylactic anticoagulation—resulting in a 60% reduction in VTE and 56% reduction in death. #ISTH2025 #VTEprevention 🩸 @marycushmanmd.bsky.social
- Reposted by Geoffrey Barnes, MD, MSc📢 New "Clot, Clot" Podcast 🎙️ Episode live from #ISTH2025‼️ A joint effort 🤝from the @isth.org and Vasculearn Network/ @thjournal.bsky.social Thieme Listen to @btsamuelsonmd.bsky.social. Erik Klok and @gbarnesmd.bsky.social about how we talk about #anticoagulation🗣️💊 www.linkedin.com/posts/vascul...
- Networking event at #ISTH2025… always a blast!! Don’t miss the next on in Paris 2026
- MAQI2 data presented at #ISTH2025 shows significant cost reductions for warfarin patients in whom unnecessary aspirin was stopped. This supports the financial benefits of a key #AntithromboticStewardship intervention.
- Patients with mechanical aortic valve replacement undergoing GI endoscopy had more bleeding but similarly low TE rate with LMWH bridging during a warfarin interruption period. #ISTH2025
- The authors note that the reduction in bleeding outcomes was longer statistically significant after multivariable adjustment. Perhaps larger sample size could help. Other prospective studies have shown reduced bleeding without LMWH bridging
- #AntithromboticStewardship can have BIG impact in the long-term care and rehab setting, but often with unique needs! #ISTH2025
- One Canadian team has audited their inpatient #AntithromboticStewardship efforts. About half of screened patients needed an intervention. And the impact has been sustained over many years! #ISTH2025
- Are you thinking of starting an #AntithromboticStewardship program? Look to your antimicrobial stewardship programs for guidance/mentorship as they have a wealth of experience to share! You may even convince one of their team members to join yours :) #ISTH2025
- What’s in a name? As we transition from Anticoagulation Stewardship to #AntithromboticStewardship in order to acknowledge the broader set of activities that improve patient outcomes, these two names will likely be used interchangeably. #ISTH2025
- Dr Tafur highlights the four domains of a Key Performance Indices scorecard. This framework is helpful for evaluating and communicating the benefit of any system-level #AntithromboticStewardship effort #ISTH2025
- Dr Tafur demonstrates an example of peri operative #AntithromboticStewardship by providing an electronic alert that automatically calculates the Caprini VTE risk score and pre-selects the option to open a prophylaxis orderset when appropriate (a behavioral nudge). #ISTH2025
- Antithrombotic agents are the leading cause of drug-related harms in Ireland (similar to US data)… highlighting the need for structured #AntithromboticStewardship programs to prevent these harms. #ISTH2025
- Hospital stewardship programs that provide education, medication review, guidelines/protocols, and facilitate transitions of care can improve outcomes AND reduce costs! #ISTH2025
- Resources that provide dedicated pharmacist, hematologist, and other clinician time for #AntithromboticStewardship is the main barrier cited by Irish clinicians. Researchers needs to focus on clinical AND financial benefits of stewardship to justify financial/resource investment. #ISTH2025
-
View full threadPharmacists can serve as the lynch pin of an #AntithromboticStewardship program given their expertise and ability to coordinate care oversight for large groups of patients. #ISTH2025
- Reposted by Geoffrey Barnes, MD, MSc[Not loaded yet]
- Reposted by Geoffrey Barnes, MD, MScThe #ISTH2025 Exhibit Hall is officially open! If you're attending, we’d love for you to swing by Booth #101 whenever you have a free moment. Come connect with our team and explore latest resources, events, and tools we offer to support your work in thrombosis and hemostasis. See you on the floor!
- I was honored to serve as a “Dragon” at this year’s INVENT network Dragon’s Den at #ISTH2025. Three exciting trials aiming to improve the diagnosis and management of thrombotic conditions were presented. Thanks to my fellow judges for a fiery good time!!!
- Practice-changing RCT at #ISTH2025 Late-Breaking Clinical Trial!!! In acute VTE patients, apixaban therapy led to less clinically-relevant bleeding than rivaroxaban for the first 3 months of therapy. Kudos to Dr Castellucci and colleagues. #COBRRA-VTE
- Dr Castellucci noted that the bleeding cumulative incidence curves seem to separate at 7days (when apixaban drops dose but riva doesn’t) and then rivaroxaban curve changes around 21 days. But separation seems to continue for entire 3 month study period. #ISTH2025
- I also find it reassuring just how low the recurrent VTE rates were in both arms. Both drugs are highly effective! So the differentiations seems to be around safety and possibly pill burden for daily vs twice failing dosing. #ISTH2025
- Reposted by Geoffrey Barnes, MD, MSc📈 Disparities in #VTE care remain a major challenge. 🧬 Race, income, region & rurality affect: • Incidence • Access to DOACs • Mortality rates We need targeted solutions rooted in data & equity. #ISTH2025 #HealthEquity #Thrombosis
- Reposted by Geoffrey Barnes, MD, MSc[Not loaded yet]
- When you are presented with a case of venous thrombosis in the setting of cancer, be sure to distinguish between Tumor Thrombus (TT) and Bland Thrombus (BT, aka VTE). #ISTH2025
- Help us understand what stewardship practices exist in health systems globally for #cvCoag and antithrombotic agents in the properties space! redcap.slhd.nsw.gov.au/surveys/?s=7... #ISTH2025 @isth.org @anticoagforum.bsky.social
- DOAC medications are first-line therapy for many thrombotic conditions. But they can interfere with some important coagulation lab studies. #ISTH2025
- People are why I always look forward to ISTH meetings. #ISTH2025
- I applaud Dr Castellucci and the entire @isth.org Control of Anticoag SSC leadership for having the vision to re-name this group to be inclusive of all antithrombotic therapies. A perfect opportunity to study and promote stewardship efforts!
- Let’s get this started!! #ISTH2025
- Reposted by Geoffrey Barnes, MD, MScThe AC Forum’s Boot Camp offers 20 expert-led sessions on anticoagulation, covering new agents, quality, and complex cases. Earn 14.5 CE credits, learn anytime, anywhere, and boost your practice. Perfect for individuals or teams. Available through September 15, 2025. Register here: bit.ly/4mPcWHK
- Reposted by Geoffrey Barnes, MD, MScWe are getting ready to welcome you at @isth.org #ISTH2025!! Any questions who is in the building and/or what D.C. stands for?
